Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
CEL-SCI Corp is a biotechnology business based in the US. CEL-SCI shares (CVM) are listed on the NYSE MKT and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $4.17 |
|---|---|
| 52-week range | $2.49 - $12.90 |
| 50-day moving average | $3.45 |
| 200-day moving average | $6.69 |
| Wall St. target price | $15.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.87 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.17 from 2022-07-05
| 1 week (2022-06-30) | -7.33% |
|---|---|
| 1 month (2022-06-03) | N/A |
| 3 months (2022-04-07) | 11.80% |
| 6 months (2022-01-06) | -38.95% |
| 1 year (2021-07-07) | -51.96% |
|---|---|
| 2 years (2020-07-07) | -69.74% |
| 3 years (2019-07-05) | 8.42 |
| 5 years (2017-07-06) | 75.95% |
| Revenue TTM | $28,558 |
|---|---|
| Gross profit TTM | $-23,108,897 |
| Return on assets TTM | -41.46% |
| Return on equity TTM | -96.97% |
| Profit margin | 0% |
| Book value | $1.04 |
| Market capitalisation | $177.6 million |
TTM: trailing 12 months
We're not expecting CEL-SCI to pay a dividend over the next 12 months.
CEL-SCI's shares were split on a 1:25 basis on 14 June 2017. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CEL-SCI shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for CEL-SCI shares which in turn could have impacted CEL-SCI's share price.
Over the last 12 months, CEL-SCI's shares have ranged in value from as little as $2.49 up to $12.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while CEL-SCI's is 2.1561. This would suggest that CEL-SCI's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.